2 Reasons to Buy Valeant Pharmaceuticals Intl. Inc.

Valeant Pharmaceuticals Intl. Inc. (TSX:VRX)(NYSE:VRX) continues to rise in price and market cap, making it a great choice for your portfolio.

The Motley Fool

When building a portfolio, investors try to balance adding stocks that pay dividends with stocks that are focused on growth. Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is clearly a candidate for the latter type of stock.

Valeant is one of the largest specialty pharmaceutical and medical device companies in the world, employing nearly 17,000 people in over 30 countries. The company is primarily focused on the development, manufacturing, licensing, and marketing of pharmaceutical products and medical devices.

Valeant’s growth strategy is predominately focused on acquiring smaller drug manufacturers and acting as a distributor of those products. This has worked well, and a number of these acquisitions have sent the stock soaring to new highs, catching the attention of many investors.

Here are two reasons why Valeant should be part of your portfolio.

1. The price keeps rising

Valeant is having an explosive year so far, greatly outperforming the market. In fact, Valeant is the best performing stock on the TSX, and has now passed a number of much larger companies in terms of market cap.

Year-to-date, the stock is up 80%, and over the past year this increased to an impressive 132%. Over the past five years, this number increases further to an astronomical 1,400%. Analysts have taken note of this, and continue to reaffirm an “outperform” rating on the stock.

Impressive as these figures are, Valeant is not showing any signs of slowing down. The stock is currently creeping higher, flirting with a 52-week high of $303.21. This comes as a welcome relief to investors watching the ongoing developments in Greece that have wreaked havoc on markets.

2. Completing the right acquisitions

Valeant has acquired more than 100 companies in the past seven years, and is in constant negotiations to acquire more. CEO Michael Pearson reinforces this, stating in a recent interview with Bloomberg that, “we’re consistently looking for good deals.”

The recent acquisitions of Bausch & Lomb and Salix Pharmaceuticals come to mind as prime examples, with the latter deal in excess of $11 billion. With each of these acquisitions, a jump in stock price follows, propelling Valeant’s market cap to over $100 billion.

Growth primarily through acquisitions comes with its own set of risks — debt is one concern, and the vulnerability of the stock if a market correction were to cause all of the individual component stocks to drop is another. Fortunately for Valeant, neither of these are major concerns at the moment.

In my opinion, a series of well executed acquisitions, impressive results, and the continued aggressive growth all ensure that Valeant remains a great option for those investors seeking growth.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

This 6.2% Dividend Stock Brings Investors Money Every Month

This 6.2%-yielding TSX dividend stock recently raised its monthly payout again, backed by rising production, strong cash flow, and promising…

Read more »

dreaming of financial success
Dividend Stocks

Passive Income: Is Enbridge Stock Still a Buy for Its Dividend Yield?

Enbridge’s resilient cash flow profile, solid payout history, and a growing earnings base strengthen its appeal as a high yield…

Read more »

diversification and asset allocation are crucial investing concepts
Dividend Stocks

How Many Enbridge Shares You Need for $1,000 in Dividends

Enbridge pays $3.88 a share. At $68.59, you need 258 shares, about $17,696, to earn $1,000 a year in annual…

Read more »

space ship model takes off
Stocks for Beginners

Max Out Your TFSA Room With 2 Canadian Stocks Poised for Growth

These two Canadian growth stocks have strong fundamentals and promising expansion plans that could help TFSA investors build solid long-term…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

3 AI Stocks Canadians May Like Better Than Nvidia

Nvidia's stock is down 32% amid controversies. Discover the implications for Nvidia and the chip industry amid these concerns.

Read more »

Business success of growth metaverse finance and investment profit graph concept or development analysis progress chart on financial market achievement strategy background with increase hand diagram
Stocks for Beginners

3 Best Growth Stocks in Canada for the Long Haul

These three Canadian growth stocks have strong business fundamentals and promising expansion opportunities that could help long-term investors build wealth.

Read more »

A airplane sits on a runway.
Investing

2 Small-Cap Stocks to Watch Right Now

With solid fundamentals and clear growth prospects, these two small-cap stocks are ideal additions to your portfolio.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, November 17

The TSX could remain volatile at the open today as investors digest Quebecor's proposed Telus takeover and Canadian Natural's Advantage…

Read more »